Zobrazeno 1 - 10
of 428
pro vyhledávání: '"Mary‐Ellen Taplin"'
Autor:
Christopher Bailey, Johann De Bono, Munitta Muthana, Mateus Crespo, Bora Gurel, Pasquale Rescigno, Matthew Fisher, Wayne A Phillips, Richard Allen, Harry Nunns, Janet E Brown, Haider Al-janabi, Katy Moyes, Anna Junker-Jensen, Helen B Pearson, Mary-Ellen Taplin, Claire E Lewis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Background Androgen deprivation therapy (ADT) is a front-line treatment for prostate cancer. In some men, their tumors can become refractory leading to the development of castration-resistant prostate cancer (CRPC). This causes tumors to regrow and m
Externí odkaz:
https://doaj.org/article/2f9585a571b74710badae3f4850ddc0f
Autor:
Mark C. Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A. Carducci, Channing J. Paller, Catherine H. Marshall, Mario A. Eisenberger, David E. Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)
Abstract Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we report the results of a multicenter, single ar
Externí odkaz:
https://doaj.org/article/48b46172ca5a4aa0833d3da4c8f53c4c
Autor:
Milena Braga-Basaria, Thomas G Travison, Mary-Ellen Taplin, Alexander Lin, Alyssa B Dufour, Daniel Habtemariam, Paul L Nguyen, Adam S Kibel, Praful Ravi, Richelle Bearup, Hannah Kackley, Hussein Kafel, Kieran Reid, Thomas Storer, Donald C Simonson, Marie McDonnell, Shehzad Basaria
Publikováno v:
PLoS ONE, Vol 18, Iss 2, p e0281508 (2023)
Androgen deprivation therapy (ADT), a cornerstone of treatment for patients with locally advanced and metastatic prostate cancer, is associated with many adverse effects, including osteoporosis, sexual dysfunction, fatigue, and vasomotor symptoms. It
Externí odkaz:
https://doaj.org/article/4cf46102272e4122abe95a4588531750
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Meng Zhou, Minjeong Ko, Anna C.H. Hoge, Kelsey Luu, Yuzhen Liu, Magdalena L. Russell, William W. Hannon, Zhenwei Zhang, Jian Carrot-Zhang, Rameen Beroukhim, Eliezer M. Van Allen, Atish D. Choudhury, Peter S. Nelson, Matthew L. Freedman, Mary-Ellen Taplin, Matthew Meyerson, Srinivas R. Viswanathan, Gavin Ha
Publikováno v:
JCI Insight, Vol 7, Iss 17 (2022)
The complex genomic landscape of prostate cancer evolves across disease states under therapeutic pressure directed toward inhibiting androgen receptor (AR) signaling. While significantly altered genes in prostate cancer have been extensively defined,
Externí odkaz:
https://doaj.org/article/6032eee655da4206a5a620a0aa119445
Autor:
Zongwei Wang, Tuo Deng, Xingbo Long, Xueming Lin, Shulin Wu, Hongbo Wang, Rongbin Ge, Zhenwei Zhang, Chin-Lee Wu, Mary-Ellen Taplin, Aria F Olumi
Publikováno v:
PLoS ONE, Vol 15, Iss 3, p e0229754 (2020)
PURPOSE:To determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC. PATIENTS AND METHODS:In a Local CRPC cohort, 42 prostatic specimens were collected from patients who wer
Externí odkaz:
https://doaj.org/article/104f90a3732d489c8d1365e8d4363a94
Autor:
Viktor A. Adalsteinsson, Gavin Ha, Samuel S. Freeman, Atish D. Choudhury, Daniel G. Stover, Heather A. Parsons, Gregory Gydush, Sarah C. Reed, Denisse Rotem, Justin Rhoades, Denis Loginov, Dimitri Livitz, Daniel Rosebrock, Ignaty Leshchiner, Jaegil Kim, Chip Stewart, Mara Rosenberg, Joshua M. Francis, Cheng-Zhong Zhang, Ofir Cohen, Coyin Oh, Huiming Ding, Paz Polak, Max Lloyd, Sairah Mahmud, Karla Helvie, Margaret S. Merrill, Rebecca A. Santiago, Edward P. O’Connor, Seong H. Jeong, Rachel Leeson, Rachel M. Barry, Joseph F. Kramkowski, Zhenwei Zhang, Laura Polacek, Jens G. Lohr, Molly Schleicher, Emily Lipscomb, Andrea Saltzman, Nelly M. Oliver, Lori Marini, Adrienne G. Waks, Lauren C. Harshman, Sara M. Tolaney, Eliezer M. Van Allen, Eric P. Winer, Nancy U. Lin, Mari Nakabayashi, Mary-Ellen Taplin, Cory M. Johannessen, Levi A. Garraway, Todd R. Golub, Jesse S. Boehm, Nikhil Wagle, Gad Getz, J. Christopher Love, Matthew Meyerson
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
Identifying the mutational landscape of tumours from cell-free DNA in the blood could help diagnostics in cancer. Here, the authors present ichorCNA, software that quantifies tumour content in cell free DNA, and they demonstrate that cell-free DNA wh
Externí odkaz:
https://doaj.org/article/8356e743a9994304930b464f7882be11
Autor:
Edoardo Francini, Fang-Shu Ou, Justin Rhoades, Eric G. Wolfe, Edward P. O’Connor, Gavin Ha, Gregory Gydush, Kaitlin M. Kelleher, Rupal S. Bhatt, Steven P. Balk, Christopher J. Sweeney, Viktor A. Adalsteinsson, Mary-Ellen Taplin, Atish D. Choudhury
Publikováno v:
Cancers, Vol 13, Iss 16, p 4055 (2021)
There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to doceta
Externí odkaz:
https://doaj.org/article/a97a14ca5dce40079676c299d35487e0
Autor:
Hyung L. Kim, Susan Halabi, Ping Li, Greg Mayhew, Jeff Simko, Andrew B. Nixon, Eric J. Small, Brian Rini, Michael J. Morris, Mary-Ellen Taplin, Daniel George
Publikováno v:
EBioMedicine, Vol 2, Iss 11, Pp 1814-1820 (2015)
Background: Prognosis associated with metastatic renal cell carcinoma (mRCC) can vary widely. Methods: This study used pretreatment nephrectomy specimens from a randomized phase III trial. Expression levels of candidate genes were determined from arc
Externí odkaz:
https://doaj.org/article/d5879eb1e7af417fb8d9f7606801fad6
Autor:
Jianneng Li, Mohammad Alyamani, Ao Zhang, Kai-Hsiung Chang, Michael Berk, Zhenfei Li, Ziqi Zhu, Marianne Petro, Cristina Magi-Galluzzi, Mary-Ellen Taplin, Jorge A Garcia, Kevin Courtney, Eric A Klein, Nima Sharifi
Publikováno v:
eLife, Vol 6 (2017)
Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail. Emerging data suggest that the glucocorticoid r
Externí odkaz:
https://doaj.org/article/7124e2fdf77d463d93e84cdc2c13fa4f